Genscript BiotechGNNSF 68 EBIT per Share is $-0.20 as of Dec. 2025. GuruFocus rates GNNSF with a GF Score™ of 68/100 and a GF Value™ of $2.81 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 1,173 Biotechnology companies, Genscript Biotech ranks worse than 85251.41% on this metric.
Genscript Biotech's EBIT per Share for the
six
months ended in Dec. 2025 was $-0.21.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.20.
During the past 12 months, the average EBIT per Share Growth Rate of Genscript Biotech was 1048.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Genscript Biotech's EBIT per Share or its related term are showing as below:
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Genscript Biotech was 70.40% per year. The lowest was -45.20% per year. And the median was -19.90% per year.
GNNSF's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.4 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Genscript Biotech (OTCPK:GNNSF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Genscript Biotech EBIT per Share Related Terms
Genscript Biotech EBIT per Share Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (GNNSF) has a EBIT per Share of $-0.20 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Genscript Biotech and its competitors. According to the industry distribution chart, Genscript Biotech ranks #999999 out of 1173 companies in the Biotechnology industry.
Is Genscript Biotech's EBIT per Share too high?
Genscript Biotech's current EBIT per Share is $-0.20. Based on the distribution chart, Genscript Biotech ranks #999999 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genscript Biotech has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #999999 out of 1173 companies for EBIT per Share. This places Genscript Biotech in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Genscript Biotech and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current EBIT per Share is $-0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.81, compared to a current price of $1.50 — trading 46.6% below its estimated fair value. The current EBIT per Share is $-0.20. Genscript Biotech's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current EBIT per Share is $-0.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of $1.50 is trading 46.6% below its estimated GF Value™ of $2.81.
GuruFocus considers Genscript Biotech to be Significantly Undervalued.
Key valuation signals for GNNSF:
EBIT per Share: $-0.20
GF Value™: $2.81 vs. price of $1.50 (46.6% below fair value)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
68GF Score
Get the complete analysis for GNNSF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
